In an expanded cohort of 147 PM/DM patients, comprising 116 patients receiving conventional therapy and 31 receiving conventional therapy plus low‐dose IL‐2, combination therapy resulted in an approximately fourfold increase in absolute Treg numbers and significant improvement in disease parameters, validating the efficacy of low‐dose IL‐2 treatment [89]. This evidence concerns the gene IL2 and dermatomyositis.